Mollie Leoni Sells 84,929 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 84,929 shares of Kura Oncology stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the transaction, the insider owned 182,345 shares in the company, valued at approximately $1,790,627.90. This trade represents a 31.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Kura Oncology Stock Up 0.2%

Shares of NASDAQ:KURA opened at $10.38 on Wednesday. The firm has a market cap of $921.43 million, a P/E ratio of -3.10 and a beta of 0.36. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09. Kura Oncology, Inc. has a 12-month low of $5.45 and a 12-month high of $12.49. The business has a fifty day simple moving average of $9.47 and a 200 day simple moving average of $9.22.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The firm had revenue of $18.27 million for the quarter, compared to analyst estimates of $25.97 million. Analysts predict that Kura Oncology, Inc. will post -3.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a research note on Thursday, May 28th. Wedbush dropped their target price on shares of Kura Oncology from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, March 6th. Oppenheimer set a $24.00 price target on Kura Oncology in a report on Thursday, May 28th. Finally, Wall Street Zen raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and an average target price of $25.46.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Bank of America Corp DE increased its position in shares of Kura Oncology by 46.1% during the first quarter. Bank of America Corp DE now owns 1,230,131 shares of the company’s stock worth $10,001,000 after acquiring an additional 388,003 shares in the last quarter. California State Teachers Retirement System lifted its position in Kura Oncology by 32.3% in the 1st quarter. California State Teachers Retirement System now owns 95,317 shares of the company’s stock valued at $775,000 after acquiring an additional 23,266 shares in the last quarter. Quantinno Capital Management LP boosted its stake in Kura Oncology by 130.1% during the 1st quarter. Quantinno Capital Management LP now owns 89,303 shares of the company’s stock valued at $726,000 after purchasing an additional 50,498 shares during the last quarter. Weiss Asset Management LP acquired a new position in Kura Oncology during the 1st quarter valued at about $428,000. Finally, Pale Fire Capital SE increased its holdings in Kura Oncology by 89.6% during the 1st quarter. Pale Fire Capital SE now owns 857,474 shares of the company’s stock worth $6,971,000 after purchasing an additional 405,229 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.